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1. Introduction 
Immunoassay has been widely used for quantification of proteins and small molecules in 
medical diagnostics, proteomics, drug discovery, and various biological research.1 ELISA 
(Enzyme-Linked ImmunoSorbant Assay) is the most commonly used immunoassay format.2 
Traditional ELISA assays used in clinical settings are laborious and expensive and often 
consume large quantities of reagents and patient specimen. Meanwhile, armed with the 
knowledge from genomic and proteomic study, there is an increasing demand for technologies 
that are capable of extracting high density of bio-information from limited sample volume for 
better disease diagnosis, prognosis and treatment.3 This demand has driven the development 
of low-cost, flexible and high throughput methods for simultaneous detection of multiple 
proteins in parallel in a single assay (multiplexed immunoassay). Although the first concept 
towards multiplexed immunoassay was already described in 1961 by Feinberg for “microspot’ 
test of antibody-antigen reaction in the thin agar films4, it was not demonstrated until 1989 
when Ekins described microarray technology principles in the ‘ambient analyte theory’ and 
envisioned the immense potential application in biomedical research and clinical diagnostics5. 
Since then, a great number of multiplexing platforms have been developed. Particularly, recent 
advances in technology (e.g. fluidics, optics, automated sample handling device) and 
informatics have enabled a real high-throughput multiplexed immunoassay.6-8 Today, 
multiplexed immunoassays are becoming popular and have been widely used in basic 
biomedical research due to their advantages in performing a large number of different assays 
all in a single reaction vessel from a relatively smaller sample volume with high efficiency. 
Multiplexed immunoassays are also becoming important for clinical diagnostic purpose by 
identifying multiple biomarkers for a wide range of diseases. Patterns of several biomarkers 
have better predictive value compared to detection of single analyte using ELISAs. Although 
there are still some challenges (e.g. complexity, expensive, validation requirement) for these 
tests, multiplexed protein test panels are now slowly penetrating into clinical diagnostics 
market and the time of their significant implementation is probably about to come. Several 
commercial multiplexed immunoassay platforms are available on this emerging market, 
including Luminex bead based platform, Meso Scale Discovery’s Multi Array Technology, and 
protein array platforms from Whatman, Arrylt and others.  
This article will provide an overview of multiplexed immunoassays, and will evaluate existing 
platforms with multiplexing capabilities and their applications in biomedical research and 
clinical diagnostics, and will also discuss technical challenges and future prospective. 
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2. Principle of multiplexed immunoassays 
Current multiplexed immunoassays are based on multi-marker strategies, in which high-
affinity capture ligands (antibodies or proteins/peptides) are immobilized in parallel assays. 
When incubated with biological samples, target analytes are bound to corresponding 
capture ligands, respectively. After washing to remove unbound proteins, captured targets 
are usually detected by using various labeled reporter ligands. Then target analytes are 
quantified by measuring the signal intensity of the detection label, which is either converted 
to mass units of target analyte using calibration curves (i.e. quantitative assay) or evaluated 
using cutoff calibrator (i.e. qualitative assay). Generally, there are two major approaches to 
realize multiplexed immunoassay: the use of planar microarrays or encoded-microparticle 
arrays. 
2.1 Planar microarrays 
Planar microarrays, such as protein microarrays,9, 10 are characterized by surface-
immobilized capture ligands in microspots onto a two dimensional grid. The identity of 
capture ligand at each microspot in the array is distinguished by its physical coordinates (x, 
y) in the grid (Figure 1A). Planar microarrays are highly miniaturized and parallelized 
assays, which consist of high density of microspots (usually ~300 µm in diameter; ~2000 
spots/cm2). Recent development of nanotechnology has enabled the fabrication of highly 
dense protein nanoarray (~106 spots/mm2).11 Fluorescence and chemiluminescence 
reporters are common used in planar arrays due to their high sensitivity and wide dynamic 
range. Planar microarray systems are perfect tools for ultra high-throughput screening of 
proteins due to their simplicity in preparing an array of high density of elements and in 
subsequent signal readouts. Many companies have produced protein microarrays for 
research purpose (www.biochipnet.com), and these protein based microarrays have been 
applied in the detection of many protein biomarkers, such as viral infection, cancers, and 
auto-immune diseases.12-16 
 
Fig. 1. (A) A scheme of planar microarray, which consists of two-dimensional grid of probe 
molecules (antibodies, peptides, or oligonucleotides). The identity of the probes at each spot 
in the array is known from its location in the grid. (B) An encoded particle array is 
composed of probe molecules attached to encoded particles. The identity of the probes is 
revealed by reading the particle code (Reprinted with permission of ref. 17) 
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However, planar microarrays are limited by some disadvantages, including slow reaction 
kinetics (due to surface diffusion), problems with localization of capture ligands bound to 
the 2D chip (due to the use of physical coordinates to indentify), and inflexibility of probe 
combinations used in an array (due to pre-fabricated flat surface).  
2.2 Encoded-microparticle arrays 
Encoded-microparticle array based systems (so called suspension arrays) have emerged as a 
very interesting alternative.17, 18 They are composed of encoded mciroparticles suspended in 
solution and pre-attached with capture ligands (Figure 1B). The nature of the capture 
ligands attached to each particle is revealed by deciphering the particle code. Encoded-
microparticle arrays have several advantages over planar microarrays. First, an encoded 
mciroparticle array exhibits greater sensing flexibility where different capture ligands can be 
mix-and-matched at different combinations at will. Second, suspended particles with curved 
surfaces benefit from faster diffusion and smaller steric hindrance whereas the reaction 
kinetics on a planar array is limited by a flat surface. Third, encoded microparticle arrays 
have greater reproducibility due to the use of hundreds to thousands of replicates for each 
target molecule in the same assay, which allows for high precision measurements. 
Accordingly, in this review, we will focus more on encoded microparticle array based 
multiplexed immunoassay. 
Encoded microparticle based multiplexed immunoassays use microparticles as solid phase 
and therefore require the encoding of microparticle arrays used for the efficient 
simultaneous measurement of large numbers of biological binding events in a single sample. 
An ideal microparticle encoding technique must satisfy a number of requirements, it must 
be: 1) machine-readable (decoding); 2) unaffected by the biochemical reactions; 3) robust, 
with low error rate; 4) able to encode large numbers of particles, each with a unique code; 5) 
are compatible with biomolecule attachment; and 6) able to mass production with low-cost. 
To this end, since the 1990s, different technologies for multiplexing have emerged (optical19-
28, graphical29-33, electronic34, 35, or physical36, 37 encoding) for different platforms (flow 
cytometry or fluorescence microscopy). The features of each encoding strategy are listed in 
Table 1. 
Of the many encoded technologies developed for multiplexing, optical encoding is the most 
well established encoding technique, in which the identity of the probe molecules attached 
to particles is uniquely correlated to the absorbance, fluorescence, Raman, or reflection 
spectrum of particles. The most common optical encoding method is using polymer 
microspheres internally doped with one or more fluorescent dyes.19, 20 By using fluorescent 
dyes with different emission spectra and doping at different intensity levels, microspheres 
of different codes can be obtained (Figure 2). The maximum number of codes that can be 
achieved in this way is determined by the formula: C = Nm-1, where C is the number of 
codes, N is the number of intensity levels and m is the number of dyes. For a typical 
multiplexed immunoassay, each set of microspheres with unique combinations of 
fluorescent spectral is used to attach specific capture ligand and constitutes the platform for 
specific molecular reaction (like each ELISA microwell). After coupling with the appropriate 
capture ligands, different sets of encoded microspheres can be pooled and multiplexed 
immunoassay is then carried out in a single reaction vial. The presence of bound targets to 
their respective capture ligands on the different microsphere sets can be detected with an  
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Encoding 
Strategies 
Encoding 
Materials 
Decoding & 
Detection Methods 
Limitations Ref. 
Optical 
Fluorescent dye Fluorescence  Limited codes 
 Relied on 
sophisticated 
instruments for 
readouts, 
 Potential 
interference of 
encoding and 
detection spectra 
16,17 
Quantum dots Fluorescence 18 
Chromophores Absorption 19 
Multiple 
wavelength/spatial 
fluorescence 
Fluorescence 20 
Raman tags Raman 21-24 
Silicon photonic 
crystals 
Fluorescence and 
reflectivity 
25 
Graphical 
Metal strips 
Reflectance and 
fluorescence  Sequential particle 
synthesis 
 Decoding are time-
consuming 
 High throughput 
limited 
26 
Selective 
Photobleaching 
code 
Fluorescence; 
confocal microscope 
27 
Structural pattern 
particles 
Physical pattern 28-30 
Electronic 
Radio frequency 
memory tags 
Radio frequency 
 Size limited 
 Instrument limited 
 Synthesis of the 
particle are 
expensive and slow 
31,32 
Physical 
Particle size Physical pattern  Limited codes 
 Special instrument 
33 
Particle shape Physical pattern 34 
Table 1. Summary of different microparticles encoding methods 
antibody conjugate coupled to a reported fluorescent dye. The signal intensities of reported  
dye are measured, which is used to quantify the amount of captured targets on each 
individual microsphere. Each microsphere type and thus each binding target are identified 
using the color code measured by a second fluorescence signal. Flow cytometric principle is 
the basic technology used in the analysis of optically encoded microsphere based multiplexed 
immunoassay, which generates robust, rapid, high-throughput, sensitive, and reproducible 
results for a wide range of biomedical application. 
To date, several multiplexed immunoassay platforms that based on optically encoded 
microspheres have been developed and commercialized. Three major companies market the 
instruments and materials that required for optically encoded microsphere based multiplexed 
immunoassay: the xMAP technology by Luminex, the CBA technology by Becton Dickinson 
BioSciences, and the VeraCodeTM technology by Illumina, as summarized in Table 2. 
The Luminex xMAP (Multi-Analyte Profiling) technology uses 5.5-µm microspheres that are 
internally doped with two fluorescent dyes (red and infrared) at ten different concentrations 
to produce up to 100 different sets of microspheres.38, 39 Each set of microspheres can then be 
derivatized by a specific type of capture ligand. As shown in Figure 3 for a typical sandwiched 
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Fig. 2. Optically encoded microspheres: unique microsphere sets are optical coded using a 
blend of different fluorescent intensities of two dyes and decoded by a flow cytometry. 
(Courtesy of Luminex Corp.)  
immunoassay, binding of target analyte brings reporter molecules to the microsphere 
surface. A green fluorescent dye (phycoerythrin, PE) is pre-conjugated to the reporter 
molecules and is used to indicate the occurrence of positive binding and quantify the 
amount of target analytes. The multiplexing detection is performed on a Luminex analyzer, 
where two lasers are used to quantitate the green, infrared, and red fluorescence of the 
individual microsphere as they pass through the sample cuvette. The red laser excites the 
dye molecules inside the microsphere and classifies the microsphere to its unique set (red–
infrared fluorochrome ratio measured by FL1, the classifier signal), and the green laser 
quantifies the immunoassay on the microsphere surface (reporter signal FL2). Only those 
microspheres with a complete sandwich will fluoresce in the green part of the spectrum, and 
the signal is proportional to the amount of capture analyte. The reporter signal is measured 
as the mean or median fluorescence intensity (MFI) for each microsphere set. And 
quantitation of capture analyte can be achieved with a built in standard curve in the assay. 
The Luminex xMAP technology has a unique combination of features: high through-put 
capacity, analyte quantification over a wide range of concentrations, small sample volume, 
high reproducibility, and high sensitivity. Multiplexed immunoassays have been designed 
for up to 100-plexed detection (Luminex 100/200TM). Recently, Luminex has developed a 
new instrument (FLEXMAP 3DTM) that can perform up to 500 multiplexed immunoassays 
by using three internal dyes encoded microspheres. More recently, Luminex also introduced 
the MAGPIXTM system which was based on the principle of fluorescence imaging, where 
Light Emitting Diodes (LEDs) and a CCD camera were used to replace the lasers and Photo 
Multiplying Tubes (PMTs) to deliver a cost-effective, compact, and reliable multiplexing 
platform. The features of these xMAP systems are listed in Table 3. The xMAP technology 
has been demonstrated as a powerful multiplexing method and has found applications in 
detection of human cytokines40, single nucleotide polymorphisms (SNPs)41, allergy testing42, 
infectious disease diagnosis43, and biological warfare agent screening44.  
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Instrumentation*
Luminex xMAP (Multi-
Analyte Profiling) 
(www.Luminexcorp.com)
BDTM CBA (Cytometric 
Bead Arrays) 
(www.bdbiosciences.com)
Illumina 
VeracodeTM/ 
BeadXpress 
(www.illumina.com) 
Microsphere 
5.6 m 
Polystyrene/Magnetic
7.5 m 
Polystyrene 
240 m (L) X 28 m 
(D) 
Cylindrical silica glass 
Bio-conjugation
Covalent: Sulfo-
NHS/EDC 
Covalent: Sulfo-SMCC 
Covalent: Sulfo-
NHS/EDC 
Fluorescence 
Detection 
Fluorescence signal 
detector system; PE 
(phycoerythrin) is 
normally the reporter 
molecule 
Fluorescence parameters 
and two size 
discriminators 
Bead identification 
based on optical 
‘‘signature’’ 
generated by 
diffraction; four 
fluorescent dyes can 
be used for labeling 
Multiplexing 
Capacity 
Up to 500 Up to 30 
Up to 48 for protein 
assay 
Key Features 
Most widely distributed 
platform; flexible, can 
test up to 100 analytes 
simultaneously; 
commercial kits are 
available. (New 
FlexMAP 3D system 
allows up to 500 
multiplexing capability 
and is compatible with 
both 96-and 384well 
plates 
Compatible with 
conventional flow 
cytometers and capable 
of cell-based assays 
High-purity silica 
glass beads are used to 
minimize fluorescence 
background, two-color 
laser system, digital 
coding enables 
customizable tracking 
of multiplex assay 
markers and critical 
identifiers such as 
sample ID, laboratory 
ID, and reagent kits 
(up to 24 bits) 
Applications 
Assays for cytokines, 
hormones, growth 
factors, proteinases, 
cancer markers, cardiac 
markers, metabolic 
markers, kinases/ 
phosphorylated 
proteins are available; 
can be used for 
autoimmune disease 
diagnostics, infectious 
disease diagnostics etc.
Assays for complement-
derived inflammatory 
mediators, intracellular 
signaling molecules, and 
apoptosis have been 
described. Kits for viral 
proteins and cytokines 
are available 
Feasible for up to 384-
plex genotyping 
assays. For protein 
analysis, only a 10-
plex cytokine assay is 
currently available. 
*See Ref.6 for more information 
Table 2. Overview of commercially encoded-microsphere based multiplexing technologies 
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Fig. 3. A schematic illustration of the Luminex xMAP technology: (A) Antibody detection 
and sandwich immunoassay formats performed on dye encoded microspheres. Any 
antigen-antibody-based format can be designed with a terminal reporter molecule specific to 
the laser detection system and distinct from any fluorescence of the microspheres; (B) At the 
completion of the binding assay, fluorescence intensities associated with each microsphere 
are measured by flow cytometry (Luminex 100); (C) The dot plot displays 100 distinct 
regions for each Luminex microsphere population classified on the basis of the intensities of 
two internal fluorochromes. The instrument was set to acquire at least 100 microspheres 
each of spectrally distinct populations of microspheres. (D) Multiplexed data from a random 
sample in an 8-plex assay was calculated. (Reprinted with permission of ref. 44) 
Another similar optically encoded microsphere based multiplexing platform was developed 
by Becton Dickinson BioSciences, named Cytometric Bead Array system (BDTM CBA). This 
system uses a series of 7.5 µm microspheres doped with one fluorescent dye at different 
intensities to simultaneously detect multiple analytes from a single sample.45, 46 The BDTM 
CBA combines bead-based immunoassay with sensitivity of amplified fluorescence 
detection by flow cytometry, creating a powerful multiplexed immunoassay system. The 
specific capture beads are incubated with tested samples and then mixed with PE conjugated  
www.intechopen.com
 
Advances in Immunoassay Technology 
 
150 
Features* Luminex 100/200TM FLEXMAP 3DTM MAGPIXTM 
Optics Lasers/APDs/PMTs Lasers/APDs/PMTs LED/CCD Camera 
Hardware Flow Cytometry based Flow Cytometry based Fluorescent Imager 
Beads 
Compatibility 
MagPlex® 
MicroPlex® 
SeroPlex® 
LumAvidin® 
xTAG® 
MagPlex® 
MicroPlex® 
SeroPlex® 
LumAvidin® 
xTAG® 
MagPlex® 
Multiplexing 
Capacity 
100 (80 for MagPlex®) 500 50 
Read Time ~40 mins/96 well plate ~20 mins/96 well plate
~60 mins/96 well 
plate 
Applications Protein/Nucleic Acid Protein/Nucleic Acid Protein/Nucleic Acid 
Dynamic Range ≥ 3.5 logs ≥ 4.5 logs ≥ 3.5 logs 
Microtiter Plate 96 well 96 well& 384 well 96 well 
* For more detail visit www.luminexcorp.com  
Table 3. Technical features of three Luminex XMAP systems 
 
Fig. 4. A schematic illustration of the BDTM CBA technology: After completion of the binding 
assay, the multiplexing assay was performed on a BD FACSCalibur flow cytomerry. 
Particles (7.5 µm in diameter) were internally labeled with different concentrations of a dye 
that emits strong fluorescent signals measured in the FL3 channel while displaying minimal 
fluorescence measured in the FL2 channel as shown in the two-color analysis dot plot (insert 
left). The non-overlapping nature of histograms for the bead populations are shown on the 
inset right. (Courtesy of BD Biosciences). 
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detection antibodies to form sandwich complexes. Sample data is then obtained using flow 
cytometry. The CBA analysis is designed to run on FACScan and FACalibur flow 
cytometers, where microsphere population are gated in the forward and side scatter channel 
(FSC and SSC) to draw an FL3 (bead channel) histogram (Figure 4). Each of the fluorescence 
intensity peaks identified in the FL3 histogram is first classified as an individual assay (one 
peak represents each type of analyte-bead complex). The corresponding target analyte 
concentrations are then measured by their fluorescence intensities in the FL2 reporter channel. 
While the number of assays that can be performed simultaneously (i.e. multiplexing capacity) 
is limited due to the use of one fluorescent dye for coding, the CBA assays are compatible with 
any cytometer that is equipped with a 488 nm laser, and capable of distinguishing emissions at 
576 and 670 nm. This advantage enables CBA assays to be performed on widely available 
commercial benchtop flow cytometry. The BDTM CBA systems have commercialized a larger 
number of multiplexed immunoassay kits for measurement of a variety of soluble and 
intracellular proteins, including cytokines, chemokines, growth factors, and phosphorylated 
cell signaling proteins. 
The third commercialized multiplexing platform is VeraCodeTM technology from Illumina, 
which is different from above two platforms that are based on fluorescent dye encoded 
microspheres. It uses cylindrical glass microbead (240 µm in length and 28 µm in diameter) 
etched with pre-calculated digital holograms. When illuminated with a red laser beam, the 
holographic elements diffract the beam to produce a unique image code, where each bright 
stripe represents ‘1’ and dark strip represents “0” (Figure 5). By sequential etching 
holograms onto microbeads, different patterns of codes can be obtained. The surface of the 
microbead is functionalized with carboxyl groups for covalent binding of capture ligand. 
Each set of microbead with a unique digital holographic code is used to attach a specific 
type of capture ligand for target analyte of interest. Consequently, multiplexed assays can be 
performed by pooling different microbeads embedded with unique ‘‘optical signatures’’ in 
the same reaction mixture. And the analytes are labeled with standard fluorescent reporters 
such as PE, Cy3, Cy5, or AlexaFluor dyes. The multiplexed assays are carried out on the 
Illumina BeadXpress reader, where the microbeads are deposited into a grooved plate so 
that they are aligned for reading. During analysis, the fluorescence and code are recorded 
for each microbead by using a red code-readout laser and a green report laser. The 
holographic code image in each microbead diffracts the incident read laser beam to make up 
the optical patterns of the bead code and can be detected with a CCD camera. And the green 
laser quantifies analyte binding. The company has provided carboxylated microbead sets for 
custom probe attachment. 
3. Applications of multiplexed immunoassays 
Multiplexed immunoassays allow simultaneous measurement of multiple analytes in a 
single biological sample, which enables people to obtain high density of biomolecule 
information with minimal assay time, cost and sample volume. After overcoming the 
technical hurdles in encoding, functionalizing, decoding, detecting, and improving the 
limited number of assays to be performed simultaneously, a great number of multiplexed 
immunoassay platforms, especially optically encoded microsphere based technologies, have 
been applied in wide range of fields in the biomedical research and clinical diagnostics. 
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Fig. 5. A schematic illustration of Illumina VeraCodeTM techonology: a glass bead containing 
an etched hologram is illustrated with a laser beam producing a code image. Multiplexed 
immunoassay can be performed by attached specific capture ligand to individual set of 
bead. (Courtesy of Illumina, Inc.) 
At present, the most successful and robust multiplexing technology is Luminex xMAP 
platform, which combines advanced fluidics, optics, and digital signal processing with 
proprietary microsphere technology to deliver multiplexed assay capabilities. Importantly, 
Luminex is an open technology and numerous companies have marketed the Luminex 
system, including Bio-Rad, Qiagen, Invitrogen, and Millipore ect.. And a steadily growing 
list of ready-to-use multiplexed immunoassays have also been provided by these companies 
for applications in biomarker discovery47-76, autoimmune disease diagnostics77-80, infectious 
disease diagnostics81-93, neurological diseases94-101, HLA testing102-104, and drug discovery105, 
106 (Table 4). 
For example, encoded microsphere based multiplexed immunoassays have been used to 
analyze the expression of cytokines, chemokines and growth factors in diverse samples 
(serum, plasma, and tissue culture), and therefore serve as a very straightforward approach 
for biomarker discovery.47-63 Cytokines, chemokines, and growth factors are cell signaling 
proteins that mediate a wide range of physiological responses including immunity, 
inflammation, and hematopoiesis. Changes in the levels of these biomarkers are associated 
with a spectrum of diseases ranging from tumor growth, to infections, to Parkinson's disease. 
One of the many commercially available panels for analysis of cytokines, chemokines and 
growth factors is a 53-plex by Bio-Rad. This panel can simultaneously measure levels of 53 
proteins in biological samples using encoded magnetic microspheres, which allows an 
investigator to take advantage of flexibility of microsphere arrays to develop a customized  
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Biomedical Research 
Partners* 
Assays/system Applications 
Affymetrix/Panomics 
(www.panomics.com) 
QuantiGene®, 
Procarta® 
Cardiac Markers; Celluar Signaling; 
Cytokines, Chemokines and Growth 
Factors; Endocrine; Gene Expression 
Profiling; Transcription Factors 
Bio-Rad Laboratories 
(www.bio-rad.com) 
X-Plex, Bio-
Plex® 
Celluar Signaling; Celluar Signaling; 
Cytokines, Chemokines and Growth 
Factors; Endocrine; Isotpying 
Cayman Chemical Company 
(www.caymanchem.com) 
  
Apoptosis; Cancer Markers; Cytokines; 
Endocrine 
Charles River Laboratories 
(www.criver.com) 
  
Accute Phase Inflammation; 
Autoimmune; Cancer Markers; Cardiac 
Markers; Cytokines and Chemokines; 
Endocrines; Infectious Disease 
EMD Chemicals 
(www.emdbiosciences.com)
Novagen 
WidescreenTM 
Celluar Signaling; Enzymatic Acitvity 
Hitachi/MiraiBio Group   Reagent; Hardware/Software Provider 
Indoor Biotechnologies, Inc. 
(www.inbio.com) 
MARIATM Allergy Testing; Custom Development 
Invitrogen 
(www.invitrogen.com) 
  
Accute Phase Inflammation; Apoptosis; 
Autoimmune Disease; Cytokines, 
Chemokines and Growth Factors; 
Endocrines; Matrix Metalloproteinases; 
Neuroscience; Signal Transduction 
Millipore Corporation 
(www.millipore.com) 
MilliplexTM, 
LINCOplexTM, 
Beadlyte® 
Apoptosis; Cancer Markers; Cardiac 
Markers; Cytokines, Chemokines and 
Growth Factors; Endocrines; Isotyping; 
Metabolic Markers 
Origene (www.Origen.com)   Genotyping; Transcription Factors 
PerkinElmer 
(www.perkinelmer.com) 
AutoplexTM 
Assay Automation; Hardware/Software 
Provider 
Qiagen, Inc. 
(www.qiagen.com) 
  Hardware/Software Provider 
R&D Systems 
(www.rndsystems.com) 
Fluoreokine® 
Autoimmune Diseases; Cytokines, 
Chemokines and Growth Factors; 
Endocrines; Matrix Metalloproteinases 
Rules Based Medcine 
(www.rbmmaps.com) 
Human MAPs  
Autoimmune Diseases; Cancer Markers; 
Cardiac Markers; Cytokines, 
Chemokines and Growth Factors; 
Endocrines; Infectious Diseases; 
Isotyping; Metabolic Markers  
*Visit www.luminexcorp.com for more information 
Table 4.A List of Luminex xMAP biomedical research partners and their application areas 
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Clinical Diagnostics Partners* Assays/system  Applications 
Abbott Molecular 
(www.abbottmolecular.com) 
  Molecular Infectious Disease 
Asuragen (www.asuragen.com) Signature 
Human Genetic Testing, 
Oncology 
BMD (www.bmd-net.com) 
FIDISTM, 
CARISTM 
Autoimmune Disease 
Bio-Rad Diagnostics (www.bio-
rad.com) 
Bio-Plex® 
Autoimmune Disease; Infectious 
Disease 
Eragen Biosciences 
(www.eragen.com) 
MultiCode Infectious Disease 
Celera Diagnostics 
(www.celeradiagnostics.com) 
  Human Genetic Testing 
Fisher HealthCare 
(www.fishersci.com) 
Prima 
Human Genetic Testing; 
Molecular Infectious Disease 
Focus Diagnostics 
(www.focusdx.com) 
  Infectious Disease 
Innogenetics NV 
(www.innogenetics.com) 
  Alzheimer's Disease 
INOVA Diagnostics 
(www.inovadx.com) 
QUANTA PlexTM Autoimmune Disease 
Inverness Medical Professional 
Diagnostics 
(www.invernessmedicalpd.com)
AtheNA Multi-
Lyte® 
Autoimmune Disease 
Microbionix GmbH 
(www.microbionix.com) 
  Custom Development 
Multimetrix/Progen Biotechnik 
GmbH (www.multimetrix.com) 
  
Infectious Disease; Custom 
Development 
One Lambda, Inc. 
(www.onelambda.com) 
LABSCreen, 
LABType 
HLA Testing 
Qiagen, Inc. (www.qiagen.com) 
LiquidChip TM; 
QIAPlexTM 
Molecular Infectious Disease 
Gen-Probe (www.tepnel.com) LifeMatch TM HLA Testing 
Zeus Scientific 
(www.zeusscientific.com) 
AtheNA Multi-
Lyte® 
Autoimmune Disease; Infectious 
Disease 
*Visit www.luminexcorp.com for more information 
Table 4.B List of Luminex xMAP clinical research partners and their application areas 
multiplex panel for efficient detection of protein of interest. Rules Based Medicine (RBM) 
also offers a special panel (Human DiscoveryMAP250+) for analysis of up to 250 human 
biomarkers from human serum sample using minute quantities of sample volume.  
Moreover, encoded microsphere based multiplexed immunoassay technology has also been 
used in cancer biomarker discovery.64-76 Rapid advance in the genomics and proteomics has 
generated a plenty of candidate cancer biomarkers that could be useful in early cancer 
detection and monitoring. However, the capacity to verify and validate these candidate 
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cancer biomarkers is limited, due to the requirement of rigorous testing in a large sample set 
from many diseases. Recently, Rules Based Medicine has developed a cancer biomarker 
panel (Human OncologyMAP®) for quantitative measurement of 101 cancer-associated 
serum proteins. This novel tool is based on encoded microsphere multiplexing technology 
and offers a powerful tool to aid in the discovery and development of new oncology drugs 
and diagnostics.  
Another example of application of encoded microsphere based multiplexed immunoassay 
technology is in clinical diagnostics such as autoimmune diseases or infectious diseases. 
Autoimmune diseases include a wide variety of systemic or organ-specific inflammatory 
diseases that are characterized by the aberrant activation of immune cells. Many autoimmune 
diseases are characterized by the presence of specific autoantibody types, which can be used in 
the diagnosis and classification of autoimmune diseases.77-80 The BioPlexTM 2200 ANA screen 
(Bio-Rad) and the AtheNA Multi-LyteTM ANA test system (Zesus Scientific) have obtained 
marketing approval from the US FDA. These two tests are used in the diagnostics of 
autoimmune diseases and based on the simultaneous measurement of multiple auto-
antibodies. Moreover, encoded microsphere based multiplexed immunoassay technology 
could improve diagnostics of infectious diseases by enabling the simultaneous detection of 
antibodies or antigens to multiple infectious pathogens, such as human immunodeficiency 
virus (HIV), the Hepatitis A, B, C virus, Mycobacterium tuberculosis, as well as a large number of 
other viral, bacterial and parasitic pathogens.81-93 FDA-approved assays for infectious diseases 
(e.g. EBV, HSV, MMRV, Syphilis, and ToRC assays on BioPlexTM 2200 or Multi-LyteTM) are 
already available on market.  
Encoded microsphere based multiplexed immunoassays are also effective tools for 
simultaneously measurement of several biomarkers in Alzheimer’s disease (AD).94, 95 
Alzheimer disease is the most common form of age-related neurodegenerative disease, 
which is a neurodegenerative disorder characterized by accumulation of intracellular 
neurofibrillary tangles and extracellular amyloid plaques throughout the cortical and limbic 
brain regions. The development of validated biomarkers for Alzheimer’s disease is essential 
to improve diagnosis and accelerate the development of new therapies. As the list of AD 
biomarkers is constantly growing, the ability to validate a panel of biomarkers becomes 
essential. To this end, Innogenetics has offered a multiparameter bead-based immunoassay 
(INNO-BIA AlzBio3) for the simultaneous quantification of 3 key AD markers in human 
cerebrospinal fluid (CSF): beta-amyloid 1-42, total tau, and tau phosphorylated at threonine 
181. 
4. Challenges and limitations of current multiplexed immunoassays 
Although hundreds of multiplexed immunoassays are introduced to the research market in 
recent years, only a limited numbers of them have been approved by the FDA for clinical 
use. The multiplexed immunoassay, as an emerging technology, is not without limitation. 
Most FDA approved multiplexed immunoassay platforms are based on encoded 
microsphere arrays by flow cytometry. Development of robust multiplexed immunoassay 
required rigorous validation of assay configuration and analytical performance to 
minimized assay imprecision and inaccuracy. Current limitations associated with 
multiplexed immunoassay technologies include selection of multiple matched antibodies 
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pairs; cross-reactivity between antibodies and analytes and assay diluents; interference from 
matrix effect; the required compromise of the assay parameters when developing multiple 
assays; and the requirement for pre-labeling reporter molecules for detection 
A major challenge of developing multiplexed immunoassay is the need to obtain a large 
number of highly specific antibodies for a wide range of analytes. Although there are many 
monoclonal and polyclonal antibodies commercially available, it is difficult to standardize 
and screen several hundreds of these antibodies to produce reliable assay in a multiplexed 
format while fulfilling the required assay sensitivity and specificity. Particularly, antibodies 
suitable for monoplex immunoassays may display cross-reactivity with other analytes in the 
multiplexed format. Cross reactivity between antibodies and nonspecific analytes limits the 
number of antibodies that can be used in a given multiplexed assay. To solve this problem, 
several attempts have been made to optimize antibodies characterization and selection by 
using high-throughput methods based on multiplexed immobilized proteins or peptides. 
For example, Poetz et al.107 reported the use of a protein microarray to simultaneously 
analyze epitope recognition and binding affinity of antibodies to determine their specificity 
and affinity.114 And Schwenk et al.108 also reported the use of Luminex platform to determine 
antibody specificity towards up to 100 antigens.  
Another major problem is that multiplexed immunoassays are prone to interference due to 
matrix effect, like any other immunoassay.109 A matrix consists of all the components in the 
sample other than the analyte. The interference from matrix would limit the performance of 
multiplexed assays. Potential sources of interference in the multiplexed immunoassay 
include endogenous plasma/serum proteins, heterophilic antibodies, soluble receptors, 
complement components, immune complexes, histidine-rich glycolproteins, lysozyme, 
fibrinogen, lectins, and some acute phase proteins.110-112 To minimize matrix effect, it is 
important to select suitable blocker, assay diluents and appropriate dilution factor for the 
sample matrix that mimics real sample during assay development.113 However, it is a 
challenge in the multiplexed format to select assay diluents that interact effectively with all 
the reagents and proteins, because each protein requires specific conditions to maintain its 
conformation. Minor changes in buffer pH and ionic strength may change the protein 
structure, thus impairing assay performance.  
Multiplexed immunoassays involve two or more capture molecules and allow the 
simultaneous measurement of different target analytes. In a monoplex immunoassay 
(ELISA), the assay parameters such as antibody pairs, sample diluents, and conjugate 
concentration can be easily optimized for a particular assay. However, in a multiplexed 
format, those parameters would be different from one analyte to another. They have to be 
adjusted to suit all the analytes within the multiplexed assay. The required compromise of 
the assay parameters would limit the assay performance of multiplexed immunoassay. 
Another major issue that limits the assay performance of multiplexed immunoassay is that 
an increasing number of detection antibodies results in an increase of background noise, 
which subsequently decreases assay sensitivity. For example, it has been found that the 
sensitivity of an 11-plex assay decreased by a factor of 1.75-5.0, compared with monoplex 
ELISA, due to an increasing in background signal in the multiplexed format.114  
Current multiplexed immunoassay platforms, based on either planar microarrays or 
suspended encoding particle arrays, often require an extra labeling step for the detection 
ligand with reporter molecules (e.g. fluorescent dye), which prolongs the assay time and 
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increases the assay cost. Therefore, challenges in simplifying the tagging process and 
eliminating the need for pre-labeling reporter molecules for detection still remain. The need to 
overcome such hurdles has motivated research into the development of a label-free 
multiplexed assay system, where progress has been made in surface plasmon resonance (SPR) 
and fluorescent conjugated polymers-based optical detection, nanowire-based electrical or 
electrochemical measurements, and mass spectrometry (MS)-based high-throughput 
screening.115-118 Conjugated polymers, especially conjugated polythiophene derivatives, can 
display remarkable changes of optical properties due to conformational changes of polymer 
chains when binding to biomolecules, therefore offer a potential opportunity as the optical 
probe for multiplexed assay in a label-free fashion.119-121 We have integrated fluorescent 
conjugated polymers into metallic encoded nanorods for label-free, multiplexed detection of 
DNA and cancer biomarkers with high specificity and sensitivity.122, 123 
5. Summary and future prospect of multiplexed immunoassay 
Multiplexed immunoassays allow simultaneous measurement of multiple proteins in a 
single biological sample. They have demonstrated comparable sensitivity to traditional 
ELISAs, making them great potential for both basic research and clinical diagnostics where 
assays required multiplexing in small sample volume. Currently, a great numbers of 
multiplexing technologies have been developed and used in the biomedical research and 
clinical diagnostics. The optically encoded microsphere-based technology is the most 
advanced multiplexing technology and has been commercialized on the market. Optically 
encoded microsphere-based technology offers a robust and efficient approach for setting up 
multiplexed assays and makes multiplexing assays feasible by flow cytometry. However, 
there are still a number of challenges to be overcome before encoded microsphere based 
multiplexing platforms can be fully applied in the field of clinical diagnostics. The need to 
overcome these challenges motivate people to continue to develop robust, sensitive, specific, 
rapid, and high-through assays with multiplex capabilities that can fulfill the expectations 
and demands for basic biomedical research and clinical application. Prospective technology 
development and research direction of multiplexed immunoassays would focus on the 
following main areas: 
5.1 Miniaturization 
Miniaturization has been a driver in assay development for many years. The goal is to 
obtain increasing amounts of molecular information from ever decreasing volumes of 
sample. Miniaturized multiplexed immunoassays can be regarded as an ideal solution for 
applications in which several parameters of a single sample with limited volume needed to 
be analyzed in parallel.124 Recent development in the microfluidic system offers great 
potential in the miniaturized immunoassay.125 The most common microfluidic platform relies 
on networks of enclosed micron-dimension channels, where fluids exhibit laminar flow (i.e. 
fluidic streams) that flow parallel to each other, and mixing occurs only by diffusion.126 
Microfluidic immunoassays have several advantages over conventional methods127: (1) 
increased surface area to volume ratios speeds up molecule binding reactions; (2) smaller 
dimensions reduce the consumption of expensive reagents and precious samples; and (3) 
automated fluid handling can improve reproducibility and throughput. These advantages 
can potentially improve assay performance and reduce the operation cost of conventional 
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immunoassays. Diercks et al. have reported the integration of optically encoded 
microspheres with microfluidic platform for miniaturized multiplexed immunoassays.128 In 
this work, the encoded microspheres were trapped in a microchannel and imaged using a 
confocal microscope. They detected four different analytes from a 2.7-nL sample.  
5.2 Automation 
Immunoassay automation promises to be the most rapidly growing area for research and 
development in the clinical diagnostics industry.129 In the automated assays, all stages of 
assays, from sample preparation to instrument operation to data processing are highly 
compatible with robotics and automation. Therefore, automation can reduce labor 
requirements and reduce testing costs. Quality testing can be achieved with immunoassay 
automation due to improved assay performance resulting from improved precision, 
sensitivity, and wide dynamic ranges, as well as from the elimination of sample handling and 
processing errors. Bio-Rad has developed a fully automated, random access multiplexed 
testing platform, Bio-PlexTM 2200. It combines the encoded magnetic microsphere with 
automated liquid handling workstation. This system addresses the needs for high-throughput 
analysis of clinical samples, which automatically processes up to 100 samples per hour, for a 
maximum of 2200 reportable results with eight hours of walk-away capability. First results are 
available in approximately 20–45 minutes (assay dependent), with subsequent patient samples 
completed approximately every 30 seconds. 
5.3 Improved capture ligands 
A key step for development of robust immunoassays is generation and characterization of 
capture ligands. These systems required high quality of capture ligands with high specificity 
and sensitivity of recognizing target proteins. Current available antibodies may display 
cross reactivity with other proteins in the multiplexed assay format. To solve this problem, 
alternative capture ligands such as engineered protein scaffolds and nucleic acid scaffolds 
are being evaluated to replace antibodies for the specific protein detection130-132. For 
example, aptamers, highly specific oligonucleic acids or peptide molecules that bind to 
protein due to their unique three dimensional structure, possess target recognition features 
as antibodies 133 
5.4 Improved encoding technology 
The development of new encoding technology for microparticles may also offer higher and 
more stable multiplexing capacity. Recent advances in Quantum dots studies have shown a 
potential for new alternative optical encoding technology. Quantum dots are 
photoluminescent semiconductor nanocrystals, which typically consist of a core of cadmium 
selenide (CdSe) surrounded by a shell of zinc sulfide (ZnS).134, 135 Quantum dots have many 
advantages over traditional fluorescent dyes as ideal fluorophores for wavelength and 
intensity multiplxing: (1) their emission spectra are tunable by the size of quantum dots, (2) 
Quantum dots of different emission profiles can be excited simultaneously at the same 
excitation wavelength, (3) their emission bands are relatively narrow, which allow more 
emission bands to be resolved with minimal spectra overlap, and (4) Quantum dots have 
higher quantum yields than most fluorescent dyes and have better photochemical stability 
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against photo-bleaching. Multicolor optical coding can be achieved by embedding different 
size of Quantum dots into polymeric microsphere at precisely controlled ratios. 136-138 For 
example, the use 10 intensity levels and 6 colors can generate up to 106 codes, which open 
up new opportunities for gene profiling, high-throughput screening, and medical 
diagnostics.  
5.5 Improved clinical applications 
Early stage detection of many diseases requires distinct pattern recognition of various 
protein biomarkers to identify at-risk individuals with adequate confidence. Multi-
biomarker strategies improve medical diagnostic and prognostic information. Therefore, 
multiplexed immunoassays are becoming more and more important for clinical diagnostics 
in the future due to their ability of identifying multiple clinical biomarkers for a wide range 
of diseases. Multiplexed protein test panels for use in cancer, stroke, diabetes, and 
cardiovascular diseases would be the interest in the future.  
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